托珠单抗静脉与皮下给药治疗大动脉炎的对比:多中心回顾性研究
该多中心回顾性研究纳入109例大动脉炎患者,比较托珠单抗静脉与皮下给药的有效性和安全性。6个月完全缓解率静脉组57例(70%)与皮下组11例(69%)无显著差异(p=0.95);皮下给药组复发风险显著更高(HR=2.55,95%CI 1.08至6.02;p=0.033)。
要点
- 6个月完全缓解率静脉组57例(70%)vs皮下组11例(69%),p=0.95,无显著差异。
- 皮下给药组复发风险显著高于静脉组(HR=2.55,95%CI 1.08至6.02;p=0.033)。
- 多因素分析中,年龄<30岁(OR 2.85,95%CI 1.14至7.12;p=0.027)和诊断至托珠单抗启用时间(OR 1.18,95%CI 1.02至1.36;p=0.034)与6个月完全缓解相关。
核心结论
- 本研究证实托珠单抗对大动脉炎有效,70%的疾病改善抗风湿药难治性大动脉炎患者在6个月时达到完全缓解。
研究设计与样本
- 多中心回顾性研究,纳入2017年1月至2019年9月期间来自法国、意大利、西班牙、亚美尼亚、以色列、日本、突尼斯和俄罗斯转诊中心的109例接受至少3个月托珠单抗治疗的大动脉炎患者。
- 109例中91例接受静脉托珠单抗,18例接受皮下托珠单抗。
主要发现
- 6个月完全缓解(NIH<2且泼尼松<7.5 mg/天)见于69%的大动脉炎患者,其中静脉组57例(70%)、皮下组11例(69%)(p=0.95)。
- 多因素分析中,与6个月完全缓解相关的因素仅为年龄<30岁(OR 2.85,95%CI 1.14至7.12;p=0.027)和从大动脉炎诊断至托珠单抗启用时间(OR 1.18,95%CI 1.02至1.36;p=0.034)。
- 静脉组中位随访30.1个月(0.4;105.8),皮下组中位随访10.8个月(0.1;46.4)(p<0.0001);皮下给药组复发风险显著更高(HR=2.55,95%CI 1.08至6.02;p=0.033)。
- 大动脉炎患者12个月复发总体累积发生率为13.7%(95%CI 7.6%至21.5%),静脉组为10.3%(95%CI 4.8%至18.4%),皮下组为30.9%(95%CI 10.5%至54.2%)。
- 不良事件发生于静脉组14例(15%)和皮下组2例(11%)。
关键数值与推荐
- 6个月完全缓解定义为NIH<2且泼尼松<7.5 mg/天。
- 6个月完全缓解率:静脉组57例(70%)vs皮下组11例(69%)(p=0.95)。
- 复发风险:皮下组vs静脉组HR=2.55(95%CI 1.08至6.02;p=0.033)。
- 12个月复发累积发生率:静脉组10.3%(95%CI 4.8%至18.4%)vs皮下组30.9%(95%CI 10.5%至54.2%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In this large multicentre study, we compared the effectiveness and safety of tocilizumab intravenous versus subcutaneous (SC) in 109 Takayasu arteritis (TAK) patients. METHODS: We conducted a retrospective multicentre study in referral centres from France, Italy, Spain, Armenia, Israel, Japan, Tunisia and Russia regarding biological-targeted therapies in TAK, since January 2017 to September 2019. RESULTS: A total of 109 TAK patients received at least 3 months tocilizumab therapy and were included in this study. Among them, 91 and 18 patients received intravenous and SC tocilizumab, respectively. A complete response (NIH <2 with less than 7.5 mg/day of prednisone) at 6 months was evidenced in 69% of TAK patients, of whom 57 (70%) and 11 (69%) patients were on intravenous and SC tocilizumab, respectively (p=0.95). The factors associated with complete response to tocilizumab at 6 months in multivariate analysis, only age <30 years (OR 2.85, 95% CI 1.14 to 7.12; p=0.027) and time between TAK diagnosis and tocilizumab initiation (OR 1.18, 95% CI 1.02 to 1.36; p=0.034). During the median follow-up of 30.1 months (0.4; 105.8) and 10.8 (0.1; 46.4) (p<0.0001) in patients who received tocilizumab in intravenous and SC forms, respectively, the risk of relapse was significantly higher in TAK patients on SC tocilizumab (HR=2.55, 95% CI 1.08 to 6.02; p=0.033). The overall cumulative incidence of relapse at 12 months in TAK patients was at 13.7% (95% CI 7.6% to 21.5%), with 10.3% (95% CI 4.8% to 18.4%) for those on intravenous tocilizumab vs 30.9% (95% CI 10.5% to 54.2%) for patients receiving SC tocilizumab. Adverse events occurred in 14 (15%) patients on intravenous route and in 2 (11%) on SC tocilizumab. CONCLUSION: In this study, we confirm that tocilizumab is effective in TAK, with complete remission being achieving by 70% of disease-modifying antirheumatic drugs-refractory TAK patients at 6 months.
引用
- Mekinian A, Biard L, Lorenzo D, et al. Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study. RMD Open. 2023. PMID: 37321669. doi:10.1136/rmdopen-2022-002830
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。